Related Experiment Video
Updated: May 27, 2025
10:52
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
Published on: December 10, 2021
2.4K
Huntington's Disease Clinical Trials Update: September 2024
Mena Farag1, Sarah J Tabrizi1, Edward J Wild1
1Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
Journal of Huntington'S Disease
|February 20, 2025
Summary
This update reviews Huntington's disease clinical trials, featuring interim results for PTC518, AMT-130, and WVE-003. It also lists all current Huntington's disease trials for researchers and patients.
Area of Science:
- Neurology
- Genetics
- Clinical Research
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder.
- Developing effective treatments for HD remains a significant challenge.
- Clinical trials are crucial for advancing HD therapeutics.
Purpose of the Study:
- To provide an update on key ongoing clinical trials for Huntington's disease.
- To present interim results from specific HD drug development programs.
- To offer a comprehensive overview of the current HD clinical trial landscape.
Main Methods:
- Review of 12-month interim data from the PTC518 extension study.
- Analysis of 24-month interim results for the AMT-130 program.
- Examination of 28-week follow-up data for the WVE-003 (SELECT-HD trial).
- Compilation of a comprehensive list of all registered and active HD clinical trials.
Main Results:
- Presentation of interim findings from PTC Therapeutics' PTC518 study.
- Reporting of interim outcomes from uniQure's AMT-130 program.
- Summary of follow-up results for Wave Life Sciences' WVE-003.
- Inclusion of a detailed directory of current Huntington's disease clinical trials.
Conclusions:
- Ongoing clinical trials show varied interim results for potential HD therapies.
- Continued research and development are vital for addressing Huntington's disease.
- This update serves as a resource for understanding the current state of HD clinical research.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
01:26Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429
01:24Parkinson's Disease: Treatment
187
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:15Parkinson's Disease: Overview
429
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
429